Bionano to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference

Rhea-AI Summary

Bionano Genomics (Nasdaq: BNGO) has announced that its CEO, Erik Holmlin, will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 9th, 2024. The presentation is scheduled for 11:00 a.m. to 11:30 a.m. ET.

Investors and interested parties can register for the webcast through a provided link. A replay of the session will be available on the Bionano website at ir.bionano.com for at least 30 days following the conference, allowing those unable to attend live to catch up on the company's latest updates and strategic insights.

This presentation at a major investment conference suggests that Bionano Genomics is actively engaging with the investment community, potentially signaling important company developments or seeking to raise its profile among investors.

News Market Reaction

-2.19%

1 alert

-2.19% News Effect

On the day this news was published, BNGO declined 2.19%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

SAN DIEGO, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will present at the H.C. Wainwright 26^th Annual Global Investment Conference on Monday, September 9^th, 2024.

Conference & Webcast Details

Date:	September 9, 2024
Time:	11:00 a.m. to 11:30 a.m. ET
Presenter:	Erik Holmlin, PhD, CEO of Bionano
Webcast:	Link to Register

A replay / recording of the session will be available following the conference through the Bionano website at ir.bionano.com for at least 30 days.

About Bionano

Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. The Company also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also offers OGM-based diagnostic testing services. For more information, visit bionano.com and bionanolaboratories.com.

Unless specifically noted otherwise, Bionano’s OGM products are for research use only and not for use in diagnostic procedures.

CONTACTS

Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionano.com

Investor Relations:
David Holmes
Gilmartin Group
+1 (858) 888-7625
IR@bionano.com

FAQ

When is Bionano Genomics (BNGO) presenting at the H.C. Wainwright Global Investment Conference?

Bionano Genomics (BNGO) is presenting at the H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9th, 2024, from 11:00 a.m. to 11:30 a.m. ET.

Who will be presenting for Bionano Genomics (BNGO) at the investment conference?

Erik Holmlin, PhD, the president and chief executive officer of Bionano Genomics, will be presenting at the H.C. Wainwright 26th Annual Global Investment Conference.

How can investors access Bionano Genomics' (BNGO) presentation at the H.C. Wainwright conference?

Investors can access Bionano Genomics' presentation through a webcast. A link to register for the webcast is provided, and a replay will be available on the Bionano website at ir.bionano.com for at least 30 days after the conference.

What is the significance of Bionano Genomics (BNGO) presenting at this investment conference?

Bionano Genomics' presentation at the H.C. Wainwright Global Investment Conference suggests the company is actively engaging with the investment community, potentially to share important updates, discuss strategic plans, or raise its profile among investors.